← Eichor
Study identifier: NCT06628973 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Social Prescribing to Improve Adherence and Outcomes in Women With Heart Failure

Condition: Heart Failure · Cardiac Failure · Heart Decompensation  ·  Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

PhaseNA
Planned participants200
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Background: Heart Failure (HF) is the second most common cause of hospitalizations for women in North America. Non-adherence to guideline-directed medical therapy (GDMT) is associated with 50% of all treatment failures and high rates of hospitalizations and death. A recent Canadian study showed that adherence to three or more GDMT medications occurred in only 20% of Canadian HF patients. Despite clear guidelines on the pharmacologic management of HF and the introduction of new and effective drugs, adherence to GDMT in women with HF is low. Furthermore, the rates of hospitalizations have not improved in Canada over the last decade, and mortality in Canadian women with HF remains high. One explanation may be that social determinants of health (SDOH), which are known to be strong predictors of both adherence and adverse outcomes in HF, have not specifically been targeted to improve either adherence or outcomes in HF. Social prescribing (SP) is an innovative, non-medical intervention that aims to improve health by addressing SDOH. However, whether using SP to LINK clinical and social services for the benefit of socially vulnerable HF women can improve outcome is unknown. By targeting SDOH, which are strong predictors of adherence and outcomes in HF, and which have been shown to disproportionately disfavor women, SP has the potential to significantly improve medication adherence, quality of life and outcomes in women with HF. Objectives: The overall aim of this study is to assess…

This description comes directly from the study's public registry record.

Talk to the study team

Dr. Louise Pilote, MD MPH PhD FRCPC  ·  +1 514-934-1934  ·  Louise.pilote@mcgill.ca

Dr. Bulemba Katende, MD, MSc.  ·  +1 514-934-1934  ·  Bulemba.Katende@rimuhc.ca

Always discuss trial participation with your own doctor first.

Locations (2)

Research Institute of the McGill University Health CentreMontreal, Quebec, CanadaNot Yet Recruiting
Royal Victoria HospitalMontreal, Quebec, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06628973